

GENMAB A/S

ISIN: DK0010272202 WKN: - Asset Class: **Stock**

Company

2024/08/16 12:08:51



Price

1,844.00

DKK

Difference



0.05%(1.00)



Contact Details

GENMAB A/S

Tel: +45-70-20-27-28

--

Fax: +

Carl Jacobsens Vej 30, Valby
2500 Copenhagen

Web: <http://www.genmab.com>

E-mail: info@genmab.com

Company Profile

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 33,139,000,000 | | 28,377,000,000 | | 22,736,000,000 | |
| Common stock capital | | 66,000,000 | | 66,000,000 | | 66,000,000 |
| Fixed assets | 2,150,000,000 | | 1,901,000,000 | | 1,891,000,000 | |
| Equity capital of a company | | 31,610,000,000 | | 27,441,000,000 | | 22,196,000,000 |
| Cash and cash equivalents | 14,867,000,000 | | 9,893,000,000 | | 8,957,000,000 | |
| Accrued liabilities | | 0 | | 11,000,000 | | 13,000,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 2,484,000,000 | | 1,823,000,000 | | 1,568,000,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 1,195,000,000 | | 1,014,000,000 | | 863,000,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 515,000,000 | | 480,000,000 | | 487,000,000 |
| Total assets | 35,289,000,000 | 35,289,000,000 | 30,278,000,000 | 30,278,000,000 | 24,627,000,000 | 24,627,000,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|----------------------------|--------|--------|--------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 2,204 | 1,660 | 1,212 |
| Equity ratio | 89.57% | 90.63% | 90.13% |
| Debt-equity ratio | 11.64% | 10.34% | 10.95% |

Others

| | 2023 | 2022 | 2021 |
|-------------------------|--------|--------|--------|
| Tax Expense Rate | 22.80% | 21.51% | 24.48% |

GENMAB A/S

ISIN: DK0010272202 WKN: - Asset Class: **Stock**

Income statement

| | 2023 | 2022 | 2021 |
|--|----------------|----------------|---------------|
| Turnover | 16,474,000,000 | 14,595,000,000 | 8,482,000,000 |
| Net income | 4,352,000,000 | 5,522,000,000 | 3,008,000,000 |
| EBIT | 633,150,000 | 902,088,000 | 509,066,000 |
| Operating income before taxes | 5,637,000,000 | 7,035,000,000 | 3,983,000,000 |
| Cash Flow | 7,380,000,000 | 3,912,000,000 | 2,228,000,000 |
| Net interest income | 912,000,000 | 303,000,000 | 184,000,000 |
| Research and development expenses | 7,435,000,000 | 5,346,000,000 | 4,004,000,000 |
| Income taxes | 1,285,000,000 | 1,513,000,000 | 975,000,000 |
| Result from investments in subsidiaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 1,001,595 | 1,178,151 | 937,779 |

Board of Directors

| | |
|------------------------|-------------------------------|
| Deirdre Connelly | Chairman of Supervisory Board |
| Anders Gersel Pedersen | Member of Supervisory Board |
| Mijke Zachariasse | Member of Supervisory Board |
| Paolo Augusto Paoletti | Member of Supervisory Board |
| Elizabeth O'Farrell | Member of Supervisory Board |
| Martin Schultz | Member of Supervisory Board |
| Pernille Erenbjerg | Member of Supervisory Board |
| Rolf K. Hoffmann | Member of Supervisory Board |
| Takahiro Hamatani | Member of Supervisory Board |

Members of Management Board

| | |
|-------------------------|-------------------------------|
| Jan G. J. van de Winkel | Chairman of Managing Board |
| Judith Klimovsky | Member of Executive Committee |
| Martine J. van Vugt | Member of Executive Committee |
| Anthony Mancini | Member of Executive Committee |
| Anthony Pagano | Member of Executive Committee |
| Birgitte Stephensen | Member of Executive Committee |
| Christopher Cozic | Member of Executive Committee |
| Tahamtan Ahmadi | Member of Executive Committee |